Ocular Therapeutix (OCUL) Milestones Are On Track Ahead Of Analyst Day - Raymond James
Tweet Send to a Friend
Raymond James analyst, Dane Leone, reiterated his Strong Buy rating on shares of Ocular Therapeutix (NASDAQ: OCUL) ahead of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
